How Cost Plus Drugs is cutting prescription prices by bypassing pharmacy middlemen

Executive overview

A cartel of three pharmacy benefit managers (PBMs) sits between drug manufacturers and patients, capturing 30–40% of all drug spending while marking up drugs by thousands of percent. Patients pay $3,000 for drugs that cost $20 at source.

Cost Plus Drugs bypasses PBMs entirely: it buys direct from manufacturers, publishes its true cost, adds a fixed 15% margin, a $5 pharmacist fee, and $5 shipping. The result is drugs at 1–99% of the price patients previously paid.

Opacity is the PBMs' business model — transparency destroys their arbitrage.

The PBM problem

• Three PBMs control drug distribution for most US insurers, acting as opaque payment processors
• They set "list prices" of $10,000/month, then offer "70% discounts" to $3,000 — the real price is $20
• Consultants hired by large employers to manage pharmacy benefits are themselves paid by PBMs
• Legislative reform consistently lags 5–7 years behind PBM tactics; policy alone won't fix it
• Pharma companies actually make more per pill selling through Cost Plus Drugs than through PBMs

How Cost Plus Drugs works

• Prices shown as: true purchase cost + 15% margin + $5 pharmacist fee + $5 shipping
• Zero marketing spend — growth driven entirely by word of mouth in patient communities
• Pattern: zero sales for ~1 month after a drug lists, then sells out in a day once someone posts in a condition-specific Facebook group
• First drug (albendazole, $250/tablet elsewhere) required private-label packaging because the manufacturer feared PBM retaliation
• Now carries virtually every generic drug; expanding into branded drugs with J&J, Bayer, Pfizer

Manufacturing for neglected drugs

• Cost Plus built its own manufacturing operation focused on drug shortage products — drugs no one else wants to make
• Example: pediatric chemotherapy drugs, where 120,000 children die annually from lack of access
• Uses robotic arms in hermetically sealed, hydrogen-peroxide-sterilised chambers with single-use disposable flow paths
• Can pivot from one drug to another in ~4 hours
• Received a DARPA grant to miniaturise the system into deployable pods for global drug shortages

Growth and scale

• Launched direct-to-consumer in January 2022; growth immediately exceeded all projections
• Reached millions of customers; experienced 20–30% month-over-month growth through late 2022
• Prescriptions now ship within 1.5 days on average, aided by robotic pharmacy fulfilment
• Sells in bulk to health systems, independent pharmacies, and clinics — currently the fastest-growing business line
• CBS Caremark (a major PBM) launched a competing "cost plus" programme, using similar branding — a sign of competitive pressure

Mark Cuban as co-founder

• Alex cold-emailed Cuban at his public Gmail; got a reply in five minutes
• Cuban started with a small investment and became a full operational co-founder
• Handles customer service calls, website design, coding, and manufacturing operations
• Communicates on any issue, day or night, within 5–10 minutes
• Mission framing: "F up the industry"

Founder background and operating philosophy

• Started college at 13, originally tracked toward string theory physics; pivoted to MD/PhD (applied mathematics)
• Founded Cost Plus Drugs as a 501(c)3 nonprofit; Sam Altman at Y Combinator advised converting to a public benefit corporation to enable investment
• Practiced radiology throughout — one shift per week; uses medical decision-making as discipline training for startup decisions
• Attended law school night classes during residency; contract law knowledge reduces legal costs and intimidation
• Core superpower: tolerance for bureaucratic process — healthcare moves on a different timescale than tech
• Considers Cost Plus Drugs roughly 3% of the way to its end goal